BRP peptide appetite research attracted attention after Stanford scientists reported a naturally occurring peptide that reduced food intake in animal experiments. The Nature study published in March 2025 concerns BRINP2-related peptide and its effects on appetite pathways, not a treatment proven to work in people.

BRP and semaglutide act through different pathways

The experiments suggest that BRP activates pathways distinct from GLP-1 signalling, including neurons in the hypothalamus, a region involved in appetite regulation. This is an interesting biological difference from semaglutide. It does not establish that BRP is safer, avoids nausea in humans or preserves muscle better in clinical use.

How Peptide Predictor helped identify BRP

The identification of BRP was facilitated by an AI-based algorithm named Peptide Predictor. This tool scanned human protein-coding genes to predict peptides generated by the enzyme prohormone convertase 1/3, which is involved in processing prohormones into active peptides. From thousands of candidates, researchers focused on peptides likely to affect neuronal activity and energy balance.

BRP, a small 12-amino-acid peptide derived from the prohormone BRINP2, produced a notably strong activation of neuron-like cells in laboratory tests, surpassing that of GLP-1, a well-known peptide involved in appetite regulation.

What the mouse and minipig experiments measured

In lean mice and minipigs, food intake fell by up to 50% during the hour after administration in the reported experiments. Obese mice studied for two weeks lost body fat and showed improved glucose and insulin tolerance. These are short-term animal outcomes, not an expected percentage of weight loss for a person.

The animal assessments did not detect certain changes in activity, anxiety-like behaviour or faecal output under the tested conditions. Absence of those signals in a small experimental programme is different from demonstrating a favourable side-effect profile in human treatment.

What remains unknown about BRP in humans

The evidence discussed here is preclinical. The researchers described work to identify receptors and understand the pathway, alongside questions about how long the peptide’s effects last. Stanford’s account of the discovery explains the research programme and its intended next steps.

A promising discovery must still pass through clinical testing before its benefits and risks in people can be assessed. Neither the word “natural” nor a favourable animal comparison provides that evidence.

More science explainers and Svelta Labs information are available at https://sveltalabs.com.

Research Use Disclaimer: This article summarises early-stage scientific findings and does not constitute medical advice or endorsement of any specific treatment. The safety and efficacy of BRP in humans have not been established.

Sources

Nature: Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide, 2025: https://www.nature.com/articles/s41586-025-08683-y.

Stanford Medicine: BRP discovery report, 5 March 2025: https://med.stanford.edu/news/all-news/2025/03/ozempic-rival.html.